Testing the human epidermal growth factor receptor 2 (HER2) status of every newly diagnosed primary breast cancer or newly metastatic breast cancer is recommended by the College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO). [1] [2] [3] [4] HER2 testing is performed to determine whether a patient's breast cancer is likely to benefit from targeted anti-HER2 therapies, which have dramatically improved survival when added to chemotherapy regimens in patients with this aggressive form of breast cancer. [5] [6] [7] [8] [9] Pathologic and demographic associations with HER2 positivity have been noted. HER2-positive breast cancers are typically high grade (Nottingham grades 2-3) and are more likely to be hormone receptor negative. In comparison with the more common HER2-negative, estrogen receptor (ER)-positive breast cancers, HER2-positive breast cancers more frequently present at a higher stage and in younger patients. In addition, variability in the HER2 status of breast cancers in different ethnic groups has also been noted. [10] [11] [12] [13] [14] [15] The reported prevalence of HER2 positivity in breast cancer varies from as low as 10% to as high as 30% across patient samples. 7, 16 Given the unique demographic characteristics and more aggressive pathologic features of HER2-positive breast cancer, reported prevalence rates are likely influenced by the characteristics of the population examined. In addition, it is possible that HER2 positivity prevalence is influenced by the laboratory methods used to test for HER2. Since laboratories and regulatory organizations seek to reduce variation related to differences in laboratory methods, it would be useful for laboratories to be able to benchmark their HER2-positive rates with other locoregional laboratories while controlling for differences related to their testing population's characteristics.
In this study, using population-based California Cancer Registry (CCR) data, we assessed the extent of regional variability, by county and health service area (HSA), in the percentage of breast cancers reported as HER2 positive. In addition, we examined the influence of patient demographics and presenting pathologic features on geographic variation. Last, we used multivariable regression analysis to develop an algorithm to compare expected HER2-positive percentages with observed percentages by health care service area.
Materials and Methods
The CCR is a population-based cancer registry that, by state mandate, collects information on all cancers diagnosed in the state, abstracting data on patient demographics, tumor characteristics, and treatment from medical records. Using these data, we selected all invasive female breast cancers diagnosed in California from 2006 to 2011. We excluded any cases diagnosed solely on autopsy or death certificate (n = 455), not microscopically confirmed (n = 1,157), American Joint Committee on Cancer (AJCC) stage 0 (n = 993), and unknown or borderline HER2 status (N = 17,151). We also excluded cases from the Alpine HSA, as case counts from this region were too small for meaningful analysis. The final study population included 121,408 cancers.
Socioeconomic and Facility Characteristics
The CCR does not collect individual-level socioeconomic data. We used a previously developed measure to assign cases to a neighborhood socioeconomic status (nSES) quintile based on the census block group of the patient's residence at the time of diagnosis. 17, 18 The CCR has data on the first facility to report each cancer case. To characterize these reporting facilities, we calculated the nSES distribution of all cancer cases reported by that facility during the years of our study and also identified those facilities that were affiliated with National Cancer Institute (NCI)-designated cancer centers.
HSAs
The state of California contains 58 counties that are grouped into HSAs by the National Center for Health Statistics (NCHS). These are defined as being areas that are "relatively self-contained with respect to hospital care." 19 For our analysis, we used the NCI's modification of the NCHS HSAs, which allocates all counties in an HSA that cross state or Surveillance, Epidemiology, and End Results (SEER) registry boundaries into one state or SEER registry, resulting in 30 NCI-modified HSAs in California.
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Statistical Analysis
We compared the proportion of HER2-positive tumors by California county and examined the distribution of patient and tumor characteristics by HER2 status.
We then constructed a model of HER2-positive status using multivariable logistic regression. The following variables were considered for inclusion in the model: NCI-modified HSA, age at diagnosis, race/ethnicity, AJCC stage at diagnosis, tumor size, nodal involvement, histology, grade, hormone (combined estrogen and progesterone) receptor status, patient nSES quintile, marital status at diagnosis, primary payer at diagnosis, hospital nSES distribution of patients, cancer center, and year of diagnosis. Variables with a Wald type 3 P value of more than .2 (marital status and patient nSES quintile) were excluded from the final model. The variance inflation factor was used to check for multicollinearity among variables. The model was adjusted for clustering by patient and reporting hospital and weighted using inverse probability of known HER2 status (see below, propensity score weighting).
For each HSA, the expected percentage of HER2-positive tumors was predicted based on the model described above. This predicted percentage was then compared with the observed percentage, and a χ 2 test was performed to test for statistical significance.
Propensity Score Weighting
The distribution of sociodemographic and tumor characteristics differed between cases with known and unknown HER2 status. We therefore used propensity scores to balance these characteristics between groups, making our study population of known HER2 status cases more representative of all breast cancer cases in the state. A propensity score was calculated based on a multivariable logistic regression model predicting known HER2 status. Variables in this model included year of diagnosis, CCR reporting region, age, race/ethnicity, AJCC stage, tumor size, nodal involvement, histology, grade, estrogen/ progesterone receptor status, nSES quintile, marital status, primary payer at diagnosis, nSES distribution of cancer cases at the reporting hospital, and NCI-designated cancer center status of the reporting hospital. The inverse probability of treatment weights (IPTW), in this case representing the inverse probability of having known HER2 status, was derived from the propensity score and normalized by the mean IPTW. Use of these weights minimized differences in the distribution of the sociodemographic and tumor characteristics between the population with unknown and known HER2 status.
Results
In total, 121,408 cases diagnosed between 2006 and 2011 were available in the CCR database and met inclusion criteria. The overall average percentage of HER2-positive breast cancers was 16.6%. The percentage of breast cancers that was HER2 positive varied between California counties with a range of 11.6% in Marin County to 26% in Shasta County (counties with <200 cases were excluded due to their small numbers) and a median percentage of 15.9% ❚Table 1❚ and ❚Figure 1❚. In addition, there was variability in the percentage of HER2-positive breast cancers among different HSAs across the state. The lowest percentage of HER2 positivity was observed in the Santa Barbara-San Luis Obispo HSA (11.7%), while the highest percentage was in the Shasta (Redding)-Trinity HSA (23.0%) ❚Table 2❚.
Available demographic and pathologic variables that might contribute to differences in the percentage of HER2-positive breast cancers in different geographic regions were examined, including age, race/ethnicity, marital status, nSES, insurance status, AJCC stage, tumor size, grade, histologic subtype, hormone receptor status, whether or not the reporting facility was a NCI-designated cancer center, patient nSES distribution of the reporting hospital, and treatment (results shown in Table 2 ).
A higher prevalence of HER2-positive cancers was observed in patients younger than 50 years (27.6% <50 years vs 17.9% ≥50 years). The percentage of HER2-positive cancers varied by race/ethnicity, with the highest prevalence in Filipinas (24.8%), followed by Asians/ Pacific Islanders (22.3%), Chinese (21.9%), and Hispanics (20.2%). Non-Hispanic whites (14.5%) and Japanese (14.1%) had the lowest percentage of HER2-positive breast cancers. In addition, when grouped by insurance types, the highest percentage of HER2 positivity was observed in noninsured/self-pay patients (21.2%) and lowest in patients with private insurance (16.6%). Overall, the percentage of HER2-positive cases decreased with increasing socioeconomic status (SES). Reporting hospitals with more than half of patients in the highest SES category had a lower percentage of HER2-positive cancers (15.0%) compared with hospitals with the majority of patients in the lowest SES (20.2%).
Cancers with higher stage at diagnosis had higher HER2-positive percentages (14.7% for stages I-II vs 24.8% for stage ≥III). Similarly, higher grade cancers had increasingly higher percentages of HER2 positivity (4.7% for grade 1, rising to 13.7% for grade 2 and 28.0% for grade 3). Last, 31.2% of hormone receptor-negative cancers were HER2-positive compared with only 13.3% of hormone receptor-positive cancers (P < .0001). A model to predict the percentage of HER2-positive cancers was constructed using multivariable logistic regression. When the predicted percentage was compared with the observed percentage by HSA, several HSAs, including Alameda, Fresno, San Diego, and Santa Barbara, had lower than expected HER2-positive percentages, while Los Angeles, Orange, and Shasta had higher than expected percentages ❚Table 3❚ and ❚Figure 2❚.
Discussion
We found that in California, there is substantial regional variation in the percentage of reported HER2-positive breast cancers. The regional variability was explained in some part by regional differences in sociodemographic factors (age, race/ethnicity, HSA, socioeconomic status, insurance status) and disease-specific factors (stage at diagnosis, hormone receptor status, tumor size, grade). Using a multivariable ❚Figure 1❚ Map of the percentage of breast cancer cases in California counties reported as human epidermal growth factor receptor 2 (HER2) positive (counties included reported >200 cases between 2006 and 2011). The median percentage was 15.9% HER2 positive. Counties reporting percentages above this median are color-coded in red tones and counties reporting below are color-coded in blue tones to visually reflect the degree to which they deviate from the median. NA, not available.
logistic regression model to account for these factors, most health service regions had a reported percentage of HER2-positive breast cancers that fell within the expected range. However, we also identified some regions with unexpectedly low or high HER2-positive rates that ❚Table 2❚ (cont) may be due to other contributing factors. Similar analyses of other population-based data sets can help laboratories set better benchmarks for expected positivity rates of cancer biomarker test results such as HER2. These population-adjusted benchmarks may allow laboratories to identify when laboratory-related factors or other factors might be contributing to unexpectedly high or low results. While some groups have suggested that simply monitoring HER2 positivity rates by institution can be an effective way to monitor test quality, our data suggest that multiple demographic and pathologic factors will affect these rates. 21 Others have reported an increased frequency of HER2-positive cancers in patients diagnosed at a younger age and having Hispanic and Asian race/ ethnicity, higher SES, hormone receptor-negative breast cancer, and higher grade/stage tumors at presentation. [22] [23] [24] [25] [26] [27] Earlier studies of CCR data from 1999 to 2004 reported similar correlations between HER2-positive rates and these sociodemographic and clinical factors. 28 A recent multicenter German study also showed that pathologic factors influenced HER2 positivity rates between centers (including grade, hormone receptor status, histologic subtype, and nodal status). 29 However, no publications to our knowledge have reported on geographic variation in HER2 test results linked to demographic and pathologic factors. The current results allow comparison of different geographic regions and estimation of the contribution of population-related factors to the percentage of test results expected to be positive.
Our discovery of outlier regions in HER2 positivity raises the question of underlying reasons for the differences. In addition to further investigation of other demographic and population-specific factors (eg, potential genetic causes of HER2-positive breast cancer that may vary between racial/ethnic groups), an informative analysis should include examination of variables known to contribute to false-negative or false-positive HER2 results. These include preanalytic variables such as prolonged ischemic times, poor fixation, alternative fixation protocols, and other specimen-handling issues. Previous studies using the CCR reported an overall HER2 positivity rate of 22% during 1993 to 1996 and 22.7% during 1999 to 2004; however, the proportions of cases with unknown HER2 status were considerably higher in these earlier case series, and thus the HER2 positivity rates were likely artifactually inflated. 14, 28 In the current study using data from 2006 to 2011, this overall HER2-positive percentage was 16.6%. An analogous study in Utah reported a similar 17% overall HER2-postive percentage. 31 The 2007 publication of the first ASCO/CAP HER2 testing and reporting guideline is a major factor that likely influenced this change. Prior to these guidelines, as many as 18% of HER2-positive test results were estimated to be false-positive results: this estimate is based on N9831 trial ❚Figure 2❚ Observed vs expected human epidermal growth factor receptor 2-positive percentages in California by National Cancer Institute-modified health service area (HSA). Regions highlighted had higher or lower results than expected based on the multivariate logistic model (as indicated by a plus or minus sign). Alpine HSAs were excluded due to small numbers.
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Lin et al / Variability in HEr2-PositiVE brEast CanCErs and National Surgical Adjuvant Breast and Bowel Project B-31 trial data reporting local laboratory positive results that could not be confirmed when retested by central reference laboratories. 32, 33 One of the issues identified as a major cause of "false-positive" cases is overinterpretation of equivocal (2+) IHC results as positive (3+) results. 34 More recent studies looking at the impact of the recent 2013 guidelines update, which modified interpretation criteria for both IHC and ISH testing, suggest that the percentage of breast cancers reported as HER2 positive and HER2 equivocal will increase. 1, 2, [35] [36] [37] [38] [39] [40] [41] [42] [43] Our study was limited by the data available from the CCR database during the time period studied. Detailed information about HER2 testing methods was not available. Future studies using this database will have the benefit of more detail about which type of test was performed (IHC vs ISH), which may help to elucidate its influence on HER2-positive rates. While additional validation is required to determine whether the predictive model presented here can be applied beyond California, these results support the conclusion that laboratories and regulatory agencies should consider the influence of demographic factors when comparing the distribution of HER2 test results.
In conclusion, we have found significant regional variation in the percentage of breast cancers reported as HER2 positive and demonstrated the influence of various population characteristics on these percentages. By developing models that estimate the expected HER2-positive rates given the population demographics and pathology characteristics, more relevant benchmarks can be developed for regional laboratories to identify systematic issues as well as outliers.
